Southeast Asset Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.62M Sell
2,848
-2
-0.1% -$2.03K 0.29% 54
2025
Q4
$3.06M Sell
2,850
-1,436
-34% -$1.37M 0.29% 56
2025
Q3
$3.27M Buy
4,286
+3,639
+562% +$2.71M 0.36% 46
2025
Q2
$504K Buy
647
+114
+21% +$88.6K 0.06% 129
2025
Q1
$440K Buy
533
+13
+3% +$10.8K 0.05% 127
2024
Q4
$401K Hold
520
0.05% 125
2024
Q3
$460K Hold
520
0.05% 116
2024
Q2
$471K Hold
520
0.06% 110
2024
Q1
$404K Buy
520
+75
+17% +$53.4K 0.05% 124
2023
Q4
$259K Sell
445
-71
-14% -$41.4K 0.03% 147
2023
Q3
$277K Sell
516
-3
-0.6% -$1.55K 0.04% 135
2023
Q2
$244K Buy
+519
New +$218K 0.03% 140

Other funds holding LLY

Southeast Asset Advisors's LLY Position: Q1 2026 in Review

Southeast Asset Advisors reduced its Eli Lilly (LLY) stake by 0.07% in Q1 2026, selling an estimated $2.03K and leaving 2,848 shares worth $2.62M. The position accounts for 0.29% of the portfolio, ranked #54.

Southeast Asset Advisors first reported a position in LLY in Q2 2023 and has held it in 12 quarters since. The position peaked at $3.27M in Q3 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Southeast Asset Advisors held 2,848 shares of Eli Lilly worth $2.62M as of Q1 2026.
  • Southeast Asset Advisors sold 2 Eli Lilly shares in Q1 2026, an estimated $2.03K.
  • Eli Lilly made up 0.29% of Southeast Asset Advisors's portfolio in Q1 2026, its #54 holding.
  • Southeast Asset Advisors first reported a position in Eli Lilly in Q2 2023 and has held it in 12 quarters since.
  • Southeast Asset Advisors's Eli Lilly position peaked at $3.27M in Q3 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Southeast Asset Advisors's 13F filing for Q1 2026, filed 13 May 2026.